High prevalence of antibodies against canine adenovirus (CAV) type 2 in domestic dog populations in South Africa precludes the use of CAV-based recombinant rabies vaccines

Vaccine

Volumn 31, Issue 38, 2013, Pages 4177-4182

  Wright, N ^a   Jackson, F R ^b   Niezgoda, M ^b   Ellison, J A ^b   Rupprecht, C E ^b   Nel, L H ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Canine adenovirus; Oral vaccines; Rabies; South Africa

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANINE ADENOVIRUS; CONTROLLED STUDY; DOG; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RABIES; SEROPREVALENCE; SOUTH AFRICA; VACCINATION; VIRUS TYPING;

CANINE ADENOVIRUS; CANINE ADENOVIRUS TYPE 1; CANINE ADENOVIRUS TYPE2; CAV1; CAV2; CAV2-RG; ORAL VACCINES; RABIES; RABIES VIRUS; RABV; RECOMBINANT CANINE ADENOVIRUS TYPE 2 VACCINE EXPRESSING RABIES VIRUS GLYCOPROTEIN; SOUTH AFRICA;

ADENOVIRUSES, CANINE; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOG DISEASES; DOGS; RABIES; RABIES VACCINES; SEROEPIDEMIOLOGIC STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84881548116     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.089     Document Type: Article

References (52)

1. Kaare M., Lembo T., Hampson K., Ernest E., Estes A., Mentzel C., et al. Rabies control in rural Africa: evaluating strategies for effective domestic dog vaccination. Vaccine 2009, 27:152-160.
2. Nel L.H., Rupprecht CE Emergence of lyssaviruses in the old world: the case of Africa. Curr Top Microbiol Immunol 2007, 315:161-193.
3. WHO Expert Consultation on rabies World Health Organ Tech Rep Ser 2005, 931.
4. Ertl P.H.C. Novel vaccines to human rabies. PLOS Negl Trop Dis 2009, 3:e515.
5. Nel L.H., Le Roux K., Atlas R. Meeting the rabies control challenge in South Africa. Microbe 2009, 4:61-65.
6. Estrada R., Vos A., De Leon R., Müller T. Field trial with oral vaccination of dogs against rabies in the Philippines. BMC Infect Dis 2001, 1:23.
7. Cliquet F., Gurbuxani J.P., Pradhan H.K., Pattnaik B., Patil S.S., Regnault A., et al. The safety and efficacy of the oral rabies vaccine SAG2 in Indian stray dogs. Vaccine 2007, 25:3409-3418.
8. Lembo T., Hampson K., Kaare M.T., Ernest E., Knobel D., Kaswala R.R., et al. The feasibility of canine rabies elimination in africa: dispelling doubts with data. PLoS Negl Trop Dis 2010, 4:e626. 10.1371/journal.pntd.0000626.
9. Slate D., Rupprecht C.E., Rooney J.A., Donovan D., Lein D.H., Chipman R.B. Status of oral rabies vaccination in wild carnivores in the United States. Virus Res 2005, 111:68-76.
10. Cliquet F., Aubert M. Elimination of terrestrial rabies in western European countries. Dev Biol 2005, 119:185-204.
11. Slate D., Algeo T.P., Nelson K.M., Chipman R.B., Donovan D., Blanton J.D., et al. Oral rabies vaccination in North America: Opportunities, Complexities, and Challenges. PLOS Negl Trop Dis 2009, 13:e549.
12. Schumacher C.L., Coulon P., Lafay F., Benejean J., Aubert M.F.A., Barrat J., et al. SAG-2 oral rabies vaccine. Onderstepoort J Vet Res 1993, 60:459-462.
13. Fekadu M., Nesby S.L., Shaddock J.H., Schumacher C.L., Linhart S.B., Sanderlin D.W. Immunogenicity, efficacy and safety of an oral rabies vaccine (SAG-2) in dogs. Vaccine 1996, 14:465-468.
14. Masson E., Cliquet F., Aubert M., Barrat J., Aubert A., Artois M., Schumacher C.L. Safety study of the SAG2 rabies virus mutant in several non-target species with a view to its future use for the immunization of foxes in Europe. Vaccine 1996, 14:1506-1510.
15. Hanlon C.A., Niezgoda M., Morril P.A., Rupprecht C.E. Oral efficacy of an attenuated rabies vaccine in skunks and raccoons. J Wildlife Dis 2002, 38:420-427.
16. Bingham J., Schumacher C.L., Hill F.W.G., Aubert A. Efficacy of SAG-2 oral rabies vaccine in two species of jackal (Canis adustus and Canis mesomelas). Vaccine 1999, 17:551-558.
17. Knobel D.L., Liebenberg A., Du Toit J.T. Seroconversion in captive African wild dogs (Lycaon pictus) follwing administration of a chicken head bait/SAG-2 oral rabies vaccine combination. Onderstepoort J Vet Res 2003, 70:73-77.
18. Müller T., Bätza H.J., Beckert A., Bunzenthal C., Cox J.H., Freuling C.M., et al. Analysis of vaccine-virus-associated rabies cases in red foxes (Vulpes vulpes) after oral vaccination campaigns in Germany and Austria. Arch Virol 2009, 154:1081-1091.
19. Beckert A., Geue L., Vos A., Neubert A., Freuling C., Müller T. Genetic stability (in vivo) of the attenuated oral rabies virus vaccine SAD B19. Microbiol Immunol 2009, 53:16-21.
20. Wandeler A.I. Control of wildlife rabies. Rabies 1988, 365-380. Kluwer, Boston. J.B. Campbell, K.M. Charlton (Eds.).
21. Fehlner-Gardiner C., Nadin-Davis S., Armstrong J., Muldoon F., Bachmann P., Wandeler A. ERA vaccine-derived cases of rabies in wildlife and domestic animals in Ontario, Canada, 1989-2004. J Wildl Dis 2008, 44:74-85.
22. Müller T., Bätza H.J., Beckert A., Bunzenthal C., Cox J.H., Freuling C.M. Vaccine virus associated rabies cases in red foxes (Vulpes vulpes) after oral rabies vaccination campaigns in Germany and Austria. Arch Virol 2009, 154(7):1081-1091.
23. Rupprecht C.E., Blass L., Smith K., Orciari L.A., Niezgoda M., Whitfield S.G., et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 2001, 345(8):582-586.
24. Roess A.A., Rea N., Lederman E., Dato V., Chipman R., Slate D., et al. National surveillance for human and pet contact with oral rabies vaccine baits, 2001-2009. J Am Vet Assoc 2012, 15(240):163-168.
25. Henderson H., Jackson F., Bean K., Panasuk B., Niezgoda M., Slate D., et al. Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine. Vaccine 2009, 27:7194-7197.
26. Appel M., Carmichael L.E., Robson D.S. Canine adenovirus type 2-induced immunity to two canine adenoviruses in pups with maternal antibody. Am J Vet Res 1975, 36:1199-1202.
27. Fischer L., Tronel J.P., Pardo-David C., Tanner P., Colombet G., Minke J., Audonnet J.C. Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against canine distemper virus challenge. Vaccine 2002, 20:3485-3497.
28. Li J., Faber M., Papaneri A., Faber M.L., McGettigan J.P., Schnell M.J., Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology 2006, 356:147-154.
29. Hu R., Zhang S., Fooks A.R., Yuan H., Liu Y., Li H., et al. Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect 2006, 8:1090-1097.
30. Zhang S., Liu Y., Fooks A.R., Zhang F., Hu R. Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. Vaccine 2008, 26:345-350.
31. Appel M., Bistner S.I., Menegus M., Albert D.A., Carmichael L.E. Pathogenicity of low-virulence strains of two canine adenoviruses. Am J Vet Res 1973, 34:543-550.
32. Rubarth S. An acute virus disease with liver lesions in dogs (hepatitis contagiosa canis). Acta Pathol Microbiol Immunol Scand Suppl 1947, 69:1-207.
33. Yildirim Y., Kirmizigül A.H., Gökce E. Seroprevalence of canine adenovirus (CAV) infection in Kars dogs in Turkey. Y. Y. U. Vet Fak Derg 2009, 20(1):37-39.
34. Swango L.J., Wooding W.L., Binn L.N. A comparison of the pathogenesis and antigenicity of infectious canine hepatitis virus and the A26/61 virus strain (Toronto). J Am Vet Med Assoc 1970, 156:1687-1696.
35. Bohm M., Thompson H., Weir A., Hasted A.M., Maxwell N.S., Herrtage M.E. Serum antibody titers to canine parvovirus, adenovirus and distemper virus in dogs in the UK which have not been vaccinated for at least three years. Vet Rec 2004, 154:457-463.
36. Posuwan N., Payungporn S., Thontiravong A., Kitikoon P. Prevalence of respiratory viruses isolated from dogs in Thailand during 2008-2009. Biomedicine 2010, 4:563-569.
37. Akerstedt J., Lillehaug A., Larsen I., Eide N.E., Arnemo J.M., Handeland K. Serosurvey for canine distemper virus, canine adenovirus, Leptospira interrogans and Toxoplasma gondii in free-ranging canids in Scandinavia and Svalbard. J Wildl Dis 2010, 46(2):474-480.
38. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by pre-existing immunity to the vaccine carrier. J Virol 2003, 77:10780-10789.
39. Smith J.S., Yager P.A., Baer G.M. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus neutralizing antibody. Laboratory techniques in rabies 1996, 181-192. World Health Organization, Geneva. 4th ed. F.X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
40. Cleaveland S., Kaare M., Knobel D., Laurenson M.K. Canine vaccination-providing broader benefits for disease control. Vet Microbiol 2006, 117:43-50.
41. Smith J.S., Orciari L.A., Yager P.A. Molecular epidemiology of rabies in the United States. Semin Virol 1995, 6:387-400.
42. Belotto A., Leanes L.F., Schneider M.C., Tamayo H., Correa E. Overview of rabies in the Americas. Virus Res 2005, 111:5-12.
43. Olsen P., Klingeborn B., Hedhammar A. Serum antibody response to canine parvovirus, canine adenovirus 1 and canine distemper virus in dogs with known status of immunization: study of dogs in Sweden. Am J Vet Res 1988, 49(9):1460-1466.
44. Osterhaus A., Berghuis-De Vries J., Steur K. Antiviral antibodies in dogs in the Netherlands. J Vet Med B 1977, 24(2):123-133.
45. Mainka S.A., Xianmeng Q., Tingmei H., Appel M.J. Serologic survey of Gaint Pandas (Ailuropoda melanoleuca) and domestic dogs and cats in Wolong Reserve, China. J Wildl Dis 1994, 30:86-89.
46. Robinson A.J., Crerar S.K., Waight Sharma N., Muller W.J., Bradley M.P. Prevalence of serum antibodies to canine adenovirus and canine herpesvirus in the European red fox (Vulpes vulpes) in Australia. Aust Vet J 2005, 83:356-361.
47. Spencer J.A., Bingham J., Heath R., Richards B. Presence of antibodies to canine distemper virus, canine parvovirus and canine adenovirus type 1 in free-ranging jackals (Canis adustus and Canis mesomelas) in Zimbabwe. Onderstepoort J Vet Res 1999, 66:251-253.
48. Hable C.P., Hamir A.N., Snyder D.E., Joyner R., French J., Nettles V., et al. Prerequisites for oral immunization of free-ranging raccoons (Procyon lotor) with a recombinant rabies virus vaccine: study site ecology and bait system development. J Wildl Dis 1992, 28:64-79.
49. Sumner J.W., Shaddock J.H., Wu G.J., Baer G.M. Oral administration of an attenuated strain of canine adenovirus (type2) to raccoons, foxes, skunk and mongoose. Am J Vet Res 1988, 49:169-171.
50. Philippa J.D.W., Leighton P.J., Nielsen O., Pagliarulo M., Schwantje H., Shury T., et al. Antibodies to selected pathogens in free-ranging terrestrial carnivores and marine mammals in Canada. Vet Rec 2004, 155:135-140.
51. Hamir A.N., Raju N., Rupprecht C.E. Experimental oral administration of canine adenovirus (type2) to raccoons (Procyon lotori). Vet Pathol 1992, 29:509-513.
52. Root J.J., McLean R.G., Slate D., MacCarthy K.A., Osorio J.E. Potential effect of prior raccoonpox virus infection in raccoons on vaccinia-based rabies immunization. BMC Immunol 2008, 9:57.